Multiple Myeloma   

This comes up from time to time, but especially in 2025 with the multistate outbreaks and the rising adoption of bispecific antibodies (e.g., teclista...

This is rare but I've seen it twice last year! One with melanoma on nivolumab and one with lung cancer on pembrolizumab (both cases in deep remission)...

For example, per the IMROZ trial methodology, Isatuximab dosing does not change to monthly dosing until >18 cycles which can impact patient QoL and...

Or can we omit it in older patients given efficacy of these regimens? Is transplant-eligibility still an important distinction up front given options ...

Do the IMROZ and BENEFIT trials inform choice? In IMROZ, the high-risk population received only revlimid/dexamethasone maintenance. Should they have g...